Mendus AB (IMMUN)

Currency in SEK
7.180
+0.230(+3.31%)
Closed·
Advertisement
Unusual trading volume
IMMUN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.5707.900
52 wk Range
3.8608.490
Key Statistics
Prev. Close
6.95
Open
6.95
Day's Range
6.57-7.9
52 wk Range
3.86-8.49
Volume
82.22K
Average Volume (3m)
30.28K
1-Year Change
-6.5104%
Book Value / Share
8.86
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMUN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.950
Upside
+372.84%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Mendus AB News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.950
(+372.84% Upside)

Earnings

Latest Release
20/08/2026
EPS / Forecast
-0.34 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare IMMUN to Peers and Sector

Metrics to compare
IMMUN
Peers
Sector
Relationship
P/E Ratio
−4.6x−0.1x−0.4x
PEG Ratio
−0.190.000.00
Price/Book
0.9x5.0x2.6x
Price / LTM Sales
-0.0x3.0x
Upside (Analyst Target)
372.8%0.0%55.1%
Fair Value Upside
Unlock−6.9%8.2%Unlock

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company’s lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
47.38M71.45%348.27M
Public Companies & Retail Investors
18.93M28.55%139.14M
Total
66.31M100.00%487.41M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Van Herk Investments B.V.33.72%22,360,176164,347
Flerie AB (publ)21.33%14,145,242103,968

People Also Watch

3.99
PRICb
-0.99%
3.25
NETIb
+1.56%
15.50
ELTEL
+4.73%
10.500
VICOR
-5.06%

FAQ

What Is the Mendus AB (Stockholm: IMMUN) Share Price Today?

The Mendus AB stock price today is 7.180 SEK.

What Stock Exchange Does Mendus AB (IMMUN) Trade On?

Mendus AB is listed and trades on the Stockholm Stock Exchange.

What Is the Ticker (Stock Symbol) for Mendus AB?

The stock symbol (also called a 'ticker') for Mendus AB is "IMMUN."

What Is the Current Mendus AB Market Capitalisation?

As of today, Mendus AB (Stockholm: IMMUN) market cap is 476.140M SEK.

What Is Mendus AB's (IMMUN) Earnings Per Share (TTM)?

The Mendus AB EPS is currently -1.599 (Trailing Twelve Months).

When Is the Next Mendus AB Earnings Date?

Mendus AB's next earnings report will be released on 11/11/2026.

Is IMMUN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Mendus AB moving averages and other technical indicators, the daily buy/sell signal for IMMUN stock is Buy.

How Many Times Has Mendus AB Stock Split?

Mendus AB has split 4 times. (See the IMMUN stock split history page for full effective split date and price information.)

How Many Employees Does Mendus AB Have?

Mendus AB has 19 employees, based on their latest Companies House report.

What is the current trading status of Mendus AB (Stockholm: IMMUN)?

As of 13/09/2026, Mendus AB (IMMUN) is trading at a share price of 7.180 SEK, with a previous close of 6.950 SEK. The stock has fluctuated within a day range of 6.570 SEK to 7.900 SEK, while its 52-week range spans from 3.860 SEK to 8.490 SEK.

What Is Mendus AB (IMMUN) Price Target According to Analysts?

The average 12-month price target for Mendus AB is 33.950 SEK, with a high estimate of 50 SEK and a low estimate of 17.9 SEK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +372.84% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.